AbCellera Biologics Inc. - Common Shares (ABCL)
ABCL moved a median of -0.20% 30 minutes after news, and +0.05% by the close. How ABCL actually reacts to news — the realized, point-in-time move the market made, measured across 201 labeled events over the last three years with zero look-ahead.
ABCL’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 197 |
| 30-min | -0.20% | 43% | 200 |
| 60-min | +0.07% | 53% | 200 |
| to close | +0.05% | 50% | 197 |
| Middle 50% of ABCL reactions | -1.46% to +1.21% |
|---|---|
| Median reaction (30-min) | -0.20% |
| Measured reactions | 201 |
Half of all AbCellera Biologics Inc. - Common Shares news events land between -1.46% and +1.21% at 30 minutes.
Reaction stats as of 2026-08-31. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ABCL reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | -2.39% | 18% | -3.58% |
| Analyst downgrades | 12 | -0.57% | 33% | -1.51% |
| Coverage initiations | 10 | +0.04% | 50% | +1.43% |
| Rating reiterations | 24 | +0.13% | 50% | +0.94% |
Last 3 years, pulled 2026-08-31. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how ABCL ranks against every other measured name →
That’s how ABCL usually reacts — get an email when it moves on news →Email me when ABCL moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ABCL's baseline. Nothing else.
Recent ABCL events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026 | Press release | Business Wire | -0.13% | -0.09% | |
| AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants | Press release | Business Wire | +1.45% | +6.30% | |
| Form 8-K AbCellera Biologics Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +0.28% | +4.98% | |
| AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | Press release | Business Wire | -1.10% | +11.95% | |
| AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile | Press release | Business Wire | +0.80% | — | |
| Form 8-K AbCellera Biologics Inc. For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | +0.80% | — | |
| AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 | Press release | Business Wire | +0.80% | — | |
| Form 8-K AbCellera Biologics Inc. For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +0.80% | — | |
| AbCellera Reports Q2 2026 Business Results | Press release | Business Wire | +2.10% | +12.78% | |
| Form 10-Q AbCellera Biologics Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.10% | +12.78% | |
| Form 8-K AbCellera Biologics Inc. For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +2.10% | +12.78% | |
| AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions | Press release | Business Wire | +1.13% | +1.32% | |
| Form 8-K AbCellera Biologics Inc. For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | -0.09% | +1.13% | |
| An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers | Press release | Canada Newswire | +2.29% | -0.35% | |
| As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22 | Press release | Canada Newswire | -0.58% | -1.75% | |
| AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026 | Press release | Business Wire | +3.10% | -4.18% | |
| AbCellera Appoints Dr. Lynn Seely to its Board of Directors | Press release | Business Wire | -3.68% | -1.75% | |
| Form 8-K AbCellera Biologics Inc. For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | -0.38% | +0.83% | |
| As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data | Press release | Canada Newswire | -1.24% | -1.17% | |
| Form 8-K AbCellera Biologics Inc. For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | -0.88% | -4.64% | |
| Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies | Press release | Business Wire | +0.39% | +5.22% | |
| Form 8-K AbCellera Biologics Inc. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +0.52% | +0.77% | |
| AbCellera Appoints Dr. Victor Sandor to its Board of Directors | Press release | Business Wire | -0.32% | -9.36% | |
| Form 8-K AbCellera Biologics Inc. For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | -0.52% | -3.02% | |
| AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635 | Press release | Business Wire | -0.84% | +3.99% | |
| Form 10-Q AbCellera Biologics Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.84% | +3.99% | |
| Form 8-K AbCellera Biologics Inc. For: May 11 | SEC filing · Form 8-K | SEC EDGAR | -0.84% | +3.99% | |
| AbCellera to Present at Upcoming Investor Conferences in May and June 2026 | Press release | Business Wire | +2.25% | +7.16% | |
| Form ARS AbCellera Biologics Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +0.66% | |
| Form DEF 14A AbCellera Biologics Inc. For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | — | +0.39% | |
| Form DEFA14A AbCellera Biologics Inc. | SEC filing · Form DEFA14A | SEC EDGAR | — | +0.39% | |
| AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call | Press release | Business Wire | +0.00% | -2.74% | |
| AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026 | Press release | Business Wire | +0.58% | +2.62% | |
| AbCellera Reports Full Year 2025 Business Results | Press release | Business Wire | -4.17% | -5.06% | |
| Form 10-K AbCellera Biologics Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.17% | -5.06% | |
| Form 8-K AbCellera Biologics Inc. For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | -4.17% | -5.06% | |
| Form S-8 AbCellera Biologics Inc. | SEC filing · Form S-8 | SEC EDGAR | -4.17% | -5.06% | |
| AbCellera to Present at Upcoming Investor Conferences in March and April 2026 | Press release | Business Wire | -2.35% | -7.84% | |
| AbCellera to Report Full Year 2025 Financial Results on February 24, 2026 | Press release | Business Wire | -2.15% | -8.82% | |
| Form 8-K AbCellera Biologics Inc. For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -1.51% | -2.79% | |
| AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause | Press release | Business Wire | +0.00% | -2.59% | |
| AbCellera and Bruker Reach Global Settlement of Patent Litigation | Press release | Business Wire | +2.04% | +2.62% | |
| Form 8-K AbCellera Biologics Inc. For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | +0.21% | -0.49% | |
| AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 | Press release | Business Wire | +0.28% | +2.79% | |
| Form 8-K AbCellera Biologics Inc. For: Nov 24 | SEC filing · Form 8-K | SEC EDGAR | — | +0.00% | |
| Form 8-K AbCellera Biologics Inc. For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +0.63% | +0.38% | |
| AbCellera Appoints Dr. Stephen Quake to its Board of Directors | Press release | Business Wire | -3.12% | -3.36% | |
| AbCellera Reports Q3 2025 Business Results | Press release | Business Wire | -3.95% | +2.90% | |
| Form 10-Q AbCellera Biologics Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.95% | +2.90% | |
| Form 8-K AbCellera Biologics Inc. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -3.95% | +2.90% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ABCL section they belong to.
Where else ABCL is measured.
ABCL earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is AbCellera Biologics Inc. - Common Shares's median reaction calculated?
Every labeled ABCL news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 201 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of ABCL's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-31.
Does ABCL's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.